NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Stock May Be Below Fair Value After FDA Cancer Drug Approval
Eli Lilly stock has delivered a very large 5-year return, yet the current checks send a mixed signal, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while the broader valuation score leans expensive.
Eli Lilly has returned about 4.1x over the past 5 years, which puts more pressure on today’s valuation to be supported by future cash flows.
Expectations around obesity and oncology drug growth can support the current price, while ongoing regulatory and pricing...